Mucoadhesive buccal tablets of rabeprazole sodium formulation and in-vitro evaluation

Shanmugarathinam Alagarsamy; Saravanan Ravindran; Mallikarjun Vasam

Shanmugarathinam Alagarsamy BIT Campus, Anna University, Tiruchirappalli. Tamilnadu
Saravanan Ravindran QIS College of Pharmacy, Ongole, Andhra Pradesh
Mallikarjun Vasam Chaitanya College of Pharmacy Education & Research, Kishanpura, Hanamkonda, Telangana

Abstract

The present investigation describes the development of mucoadhesive tablets of Rabeprazole sodium, proton pump inhibitor, designed to prolong the gastric residence time after oral administration. Tablets were formulated using four mucoadhesive polymers namely Carbopol 934P, HPMC K4M, Guar gum and Chitosan. The formulated tablets were characterized for various quality control parameters namely, weight variation, thickness, hardness, content uniformity, swelling index, mucoadhesive force and in-vitro drug release. The swelling index of the formulations maintained for 6h were in the range of 44.3-50.4, 42.8-48.9, 38.3-45.7% for F1-F3, F4-F6, F7-F9 formulations. The in-vitro drug release studies were performed for F1 to F9 formulations and it had revealed that the formulations release was found to be in between 77.5-97.6%. F8 formulation was optimized due highest mucoadhesive strength; surface pH and drug release.

Keywords: Rabeprazole Sodium, Mucoadhesive, Buccal Tablets, Proton Pump Inhibitors, quality control parameters

Downloads

Download data is not yet available.

References

1. Niyaz SM, Punit BP, Moinuddin MS. Glimpse of Drug Delivery Systems for Proton Pump Inhibitors. International Journal of Pharmaceutical Sciences Review and Research. 2016; 36(1):81-88.
2. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739-54.
3. Saman Chubineh, MD, and John Birk, MD Proton Pump Inhibitors: The Good, the Bad, and the Unwanted. Southern Medical Journal. 2012;105(11):613-618.
4. Pace, F., Pallotta, S., Casalini, S., Porro, G. B. (2007). A review of rabeprazole in the treatment of acid-related diseases. Therapeutics and clinical risk management. 2007; 3(3), 363–379.
5. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. European Journal of Clinical Pharmacology. 2009;65(1):19-31.
6. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. Journal of Advanced Pharmaceutical Technology & Research. 2010;1(4):381-387
7. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Development and Industrial Pharmacy. 1997;23:489–515
8. Mohit B, Ankit Y, Sachin KS, Monica G, Deepak G, Harish R, Bimlesh K, Rakesh N. Formulation and Evaluation of Oral Mucoadhesive Tablets of Cisplatin. Journal of Pharmacy Research. 017,11(7),798-806
9. Shanker G, Kumar CK, Gonugunta CS, Kumar BV, Veerareddy PR. Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets. AAPS PharmSciTech. 2009;10(2):530-539.
10. Puratchikody A, Shanmugarathinam A, Hari PG, Faritha Begam N, Sridhar G. Formulation and development of sustained release metformin hydrochloride tablet. Pharma Innovation 2015;4(2):111-113
11. Vishnu MP, Bhupendra GP, Madhabhai MP. Formulation, Evaluation, and Comparison of Bilayered and Multilayered Mucoadhesive Buccal Devices of Propranolol Hydrochloride. AAPS Pharm Sci Tech; 2007. 8(1) E147–E154.
12. Ayhan S, Yalcin O, Askin I. Preparation and In vitro evaluation of sustained release tablet formulations of Diclofenac sodium. Farmaco; 2005.60(2): 171-177.
13. Doijad RC, Manvi FV, Malleshwara R, Patel PS. Buccoadhesive Drug Delivery System of Isosorbide Dinitrate: Formulation and Evaluation. Indian Journal of Pharmaceutical Sciences. 2006;68(6): 744-748
14. Chowdary KPR, Sundari GB. Design and Evaluation of mucoadhesive controlled release oral tablets of Glipizide. Indian Journal of Pharmaceutical Sciences.2003; 65 (6):591-594.